DUBLIN--(BUSINESS WIRE)--The "Radiopharmaceuticals - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin America. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.
This report analyzes the worldwide markets in US$ Thousand by the following Segments:
- Diagnostic Radiopharmaceuticals
- Therapeutic Radiopharmaceuticals
The report profiles 61 companies including many key and niche players such as:
- Actinium Pharmaceuticals Inc. (USA)
- Alliance Medical (UK)
- Alseres Pharmaceuticals Inc. (USA)
- Avid Radiopharmaceuticals (USA)
- Bayer HealthCare Pharmaceuticals (Germany)
- Bracco Diagnostics Inc. (USA)
- Cardinal Health Inc. (USA)
- GE Healthcare (UK)
- Ion Beam Applications S.A. (Belgium)
- Immunomedics Inc. (USA)
- Jubilant Pharma (India)
- Lantheus Medical Imaging Inc. (USA)
- Medi-Radiopharma Ltd. (Hungary)
- Nordion Inc. (Canada)
- Peregrine Pharmaceuticals Inc. (USA)
- PETNET Solutions Inc. (USA)
- Positron Corporation (USA)
- Triad Isotopes Inc. (USA)
Topics Covered
1. INDUSTRY OVERVIEW
- A Prelude
- Current & Future Analysis
- Diagnostic Radiopharmaceuticals: The Dominant Segment
- Select Cardiology and Oncology Radiopharmaceuticals
- New Therapeutic Radiopharmaceuticals to Drive Global Market
- Market Drivers
- Growing Acceptance in Cancer Treatment
- Increasing Acceptance of Disease-Targeted Treatment
- Growing Emphasis of Accurate Diagnosis
- Expanding Molecular Imaging Applications
- Market Restraints
- Stringent Regulatory Guidelines for Manufacture, Storage and Usage
- Global Supply Shortages
- Price Sensitivity & Competition from Alternatives
- Lack of Dosage Standards for Pediatric Patients Limits Radiopharmaceutical Efficacy
- Unfounded Fears of Radiation Exposure Hinder Growth
- Bottlenecks in Developing Markets
- Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
- Competition
- Relevant Aspects of Radiopharmaceutical Production
- Increasing Uptake of PET: A Prime Growth Driver
- Non-Reactor Based TC-99m Production to Drive SPECT Growth
- New Radiopharmaceuticals Drive Adoption of Molecular Imaging
- PET and SPECT in Cardiovascular Imaging
- Innovative Radiotracers
- Key to PET & SPECT Success in Cardiovascular Imaging
- Cardiac Amyloidosis Visualization
- A Potential Application for PET
- Application of PET in Drug Development to Expand Opportunities
- Industry Focus Gears up for innovative Radiopharmaceuticals with Therapeutic Benefits
- Innovative Radiopharmaceuticals to Boost Cardiac Applications
- Intra-operative Lymphatic Mapping (ILM): Creates New Opportunities for Radiopharmaceuticals in Cancer Detection
- Personalized Medicine to Drive Nuclear Medicine
- Rise in Incidence of Neurological Disorders to Drive Growth
- Battling Alzheimer's Disease
- A Powerful Market Force for Nuclear Medicine
- Combating the Shortage of RadioIsotopes
2. LONGSTANDING GROWTH DRIVERS
- Rise in Incidence of Cancer
- A Major Growth Driver
- Cancer Prone Sites based on Age
- Ageing Population
- A Vital Demography
- Global CVD Stats
3. PRODUCT OVERVIEW
- Radiopharmaceuticals: A Definition
- Mechanism of Action
- Application of Radiopharmaceuticals
- Radioactive Tracers for Diagnostic Imaging
- Therapeutics
- Research
- Sterilization
- Classification of Radiopharmaceuticals
- Diagnostic Radiopharmaceuticals
- Commonly Used Diagnostic Radiopharmaceutical Agents
- Major Isotopes and their Diagnostic Applications
- Advantages
- Classification
- Cardiology Diagnostics
- Non-cardiology Diagnostics
- Molecular Imaging Modalities in Radiopharmaceutical Diagnostics
- Planar Imaging
- Positron Emission Tomography (PET)
- Applications of PET
4. PRODUCT INNOVATIONS/INTRODUCTIONS
- ORA Launches NEPTIS xSeed Kitless Synthesizer
- Advanced Accelerator Applications Resubmits NDA for Lutathera
- Norgine B.V. Launches LYMPHOSEEK
- IBA launches the Fixed IFP
- Piramal Imaging and ISOLOGIC Innovative Radiopharmaceuticals Receive Approval
- FDA Approves Netspot to Detect Rare Neuroendocrine Tumors
- Blue Earth Diagnostics Bags FDA Approval for AxuminTM
- EMA Issues Positive Opinion on Marketing Authorization Application for SomaKit TOC
- IBA Unveils the Cyclone KIUBE Cyclotron
- Advanced Accelerator Expands NETSPOTTM Supply Chain
- Blue Earth Diagnostics and Siemens' PETNET Solutions Introduce AxuminTM (Fluciclovine F 18) Injection
- Blue Earth Wins FDA Approval for PET Agent for Axumin
- Zevacor to Develop SomaKit-TATE doses for AAA
- Triad Isotopes Receives FDA Approval for Fludeoxyglucose F18 (18F FDG) and Sodium Fluoride F-18
5. RECENT INDUSTRY ACTIVITY
- Telix Pharmaceuticals and ANMI Enter into Partnership for Commercialization of ANMI's 68Ga-HBED-CC-PSMA Kit
- Telix Pharmaceuticals Signs Technology Licensing Agreement and Research Collaboration with the University of Melbourne
- RadioMedix and ITM Enhter into Partnership Agreement for Distribution of Lutetium-177 in North America
- Blue Earth Diagnostics Signs Exclusive Distribution Agreement with Seibersdorf Laboratories for the supply of Axumin
- Blue Earth Diagnostics and GE Healthcare Sign Agreement to Manufacture Axumin
- IRE-ELiT Signs Exclusive Long-Term Contract with Cardinal Health
- Jubilant Acquires Radiopharmacy Business of Triad
- ARTMS Products and GE Healthcare Partner to Expand Cyclotron-Produced Radioisotopes
- Theragnostics Signs Partnership Agreement with ROTOP
- Cyclotek and Telix Pharmaceuticals Sign Radiopharmaceutical Manufacturing Agreement
- IBA and Philips Collaborate for Sales and Marketing of Proton Therapy in Brazil
- Advanced Accelerator Applications Signs Agreement with Blue Earth Diagnostics to Supply Axumin
- ARTMS Products Partners with Alliance Medical to Supply Tc-99m
- Sofie Biosciences to Acquire Zevacor Pharma
- IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Form Curium
- GE Healthcare to Supply Radiopharmaceuticals to HealthTrust
- IBA Signs Co-Marketing Agreement in North America with Nelco Worldwide
- Telix Announces Product Development Partnership with Therapeia
- IBA Signs ProteusONE Contracts with Proton Partners International
- Cellectar Biosciences Selects Hamilton for Supply of CLR 131
- Life Healthcare Acquires Alliance Medical Group
- Lantheus Holdings Divests its Australian Radiopharmacy Servicing Business
- ITEL Signed Agreement with AAA to Manufacture and Commercialize F-18 Radiopharmaceuticals
- Zevacor Pharmato Manufacture and Supply Lomab-B for Pivotal Phase 3 SIERRA Trial
- Blue Earth Diagnostics and Norsk Enter into Manufacturing and Distribution partnership for Fluciclovine (18F)
6. FOCUS ON SELECT PLAYERS
7. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 61 (including Divisions/Subsidiaries 69)
- The United States (27)
- Canada (4)
- Japan (1)
-
Europe (28)
- France (4)
- Germany (5)
- The United Kingdom (4)
- Italy (2)
- Rest of Europe (13)
- Asia-Pacific (Excluding Japan) (8)
- Africa (1)
For more information about this report visit https://www.researchandmarkets.com/research/64h5xr/radiopharmaceutica?w=4
